Oxaliplatin-related thrombocytopenia

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 1937-1942

  Jardim, D L ^a   Rodrigues, C A ^a,b   Novis, Y A S ^a   Rocha, V G ^a,c   Hoff, P M ^a,c  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Myelossupression; Oxaliplatin; Review; Thrombocytopenia

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; ELTROMBOPAG; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHYLPREDNISOLONE; OXALIPLATIN; RECOMBINANT INTERLEUKIN 11; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM;

BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CHILL; COLORECTAL CANCER; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; HEMOLYTIC UREMIC SYNDROME; HUMAN; LIVER DISEASE; LIVER FIBROSIS; LIVER METASTASIS; LIVER SINUSOID; LIVER VENOOCCLUSIVE DISEASE; MEGAKARYOCYTE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 84864960431     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds074     Document Type: Review

References (44)

1. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
2. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
3. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
4. Wu Y, Aravind S, Ranganathan G et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther 2009; 31(Pt 2): 2416-2432.
5. Bautista MA, Stevens WT, Chen CS et al. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol 2010; 3: 12.
6. Curtis BR, Kaliszewski J, Marques MB et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006; 81: 193-198.
7. Overman MJ, Maru DM, Charnsangavej C et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of Hepatic sinusoidal injury. J Clin Oncol 2010; 28: 2549-2555.
8. Slade JH, Alattar ML, Fogelman DR et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009; 8: 225-230.
9. Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.
10. Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990.
11. Angitapalli R, Litwin AM, Kumar PR et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 2009; 76: 363-368.
12. Soubrane O, Brouquet A, Zalinski S et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 2010; 251: 454-460.
13. Kauffman CR, Mahvash A, Kopetz S et al. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 2008; 112: 2283-2288.
14. Maindrault-Goebel F, Andre T, Tournigand C et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41: 2262-2267.
15. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580-587.
16. Taleghani BM, Meyer O, Fontana S et al. Oxaliplatin-induced immune pancytopenia. Transfusion 2005; 45: 704-708.
17. Pavic M, Moncharmont P, Seve P et al. Oxaliplatin-induced immune thrombocytopenia. Gastroenterol Clin Biol 2006; 30: 797-798.
18. Sorbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 2001; 40: 882-883.
19. Earle CC, Chen WY, Ryan DP, Mayer RJ. Oxaliplatin-induced Evan's syndrome. Br J Cancer 2001; 84: 441.
20. Koutras AK, Makatsoris T, Paliogianni F et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004; 67: 179-182.
21. Buti S, Ricco M, Chiesa MD et al. Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report. Anticancer Drugs 2007; 18: 297-300.
22. Cobo F, De Celis G, Pereira A et al. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. Anticancer Drugs 2007; 18: 973-976.
23. Santodirocco M, Lombardi V, Fesce C et al. Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: a case report. Acta Oncol 2008; 47: 1602-1604.
24. Shao YY, Hong RL. Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res 2008; 28: 3115-3117.
25. Fontao-Wendel R, Hoff PM, Lazar A et al. Immune-mediated pancytopenia induced by oxaliplatin: a case report. Transfusion 2010; 50: 1453-1459.
26. George JN, Raskob GE, Shah SR et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129: 886-890.
27. Akdeniz A, Kucukoztas N, Yalcin S et al. Oxaliplatin-induced immune thrombocytopenia in a patient with colon cancer. Am Surg 2011; 77: E9.
28. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
29. Zeuner A, Signore M, Martinetti D et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 2007; 67: 4767-4773.
30. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?. Crit Rev Oncol Hematol 2002; 42: 163-171.
31. Schiffer CA, Anderson KC, Bennett CL et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-1538.
32. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
33. Tsimberidou AM, Giles FJ, Khouri I et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 2005; 16: 139-145.
34. Fanucchi M, Glaspy J, Crawford J et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404-409.
35. Basser RL, Rasko JE, Clarke K et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118-3128.
36. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
37. Bennett CL, Evens AM, Andritsos LA et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-650.
38. Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol 2006; 6: 5.
39. Phan NT, Heng AE, Lautrette A et al. Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: think of acute tubular necrosis. NDT Plus 2009; 2: 254-256.
40. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005; 31: 681-690.
41. Knower MT, Bowton DL, Owen J, Dunagan DP. Quinine-induced disseminated intravascular coagulation: case report and review of the literature. Intensive Care Med 2003; 29: 1007-1011.
42. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001; 135: 1047-1051.
43. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 2003; 14: 580-585.
44. Fung MC, Storniolo AM, Nguyen B et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999; 85: 2023-2032.